NCT05379907View on ClinicalTrials.gov

Observational Study of ctDNA in Resectable and Borderline Resectable Pancreatic Cancer

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

August 23, 2022

Primary Completion Date

August 23, 2023

Study Completion Date

August 23, 2023

Conditions
Pancreatic Cancer
Interventions
OTHER

SIGNATERA™ ctDNA testing

Information collection about how SIGNATERA™ ctDNA testing changes how doctors make treatment recommendations to patients with early-stage pancreatic cancer.

Trial Locations (1)

22031

Inova Schar Cancer Institute, Fairfax

Sponsors

Collaborators (1)

Natera, Inc.
All Listed Sponsors
collaborator

Natera, Inc.

INDUSTRY

lead

Inova Health Care Services

OTHER